Solriamfetol for depression with excessive daytime sleepiness
Tests solriamfetol against placebo in adults with depression and daytime sleepiness.
Plain-language title generated from the registry record
Registry title: Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Key facts
- Where
- Atlanta, Austin, Bellaire, Bellflower, Brooklyn, Cherry Hill, Chicago, Chino, Cincinnati, Dallas, Edmond, Glendale, Houston, Imperial, Jacksonville, Las Vegas, Los Angeles, Memphis, Miami, New York, Norcross, Oceanside, Oklahoma City, Pikesville, Portland, Redlands, San Antonio, San Diego, Sherman Oaks, Snellville, Springfield, Staten Island, The Bronx, Toms River, Tucson, and Walnut Creek, United StatesSee the 36 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07484217, who can take part
Where in United States
- AtlantaAtlanta, United StatesTaking people
- AustinAustin, United StatesTaking people
- BellaireBellaire, United StatesTaking people
- BellflowerBellflower, United StatesTaking people
- BrooklynBrooklyn, United StatesTaking people
- Cherry HillCherry Hill, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- ChinoChino, United StatesTaking people
- CincinnatiCincinnati, United StatesTaking people
- DallasDallas, United StatesTaking people
- EdmondEdmond, United StatesTaking people
- GlendaleGlendale, United StatesTaking people
- HoustonHouston, United StatesTaking people
- ImperialImperial, United StatesTaking people
- JacksonvilleJacksonville, United StatesTaking people
- Las VegasLas Vegas, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- MemphisMemphis, United StatesTaking people
- MiamiMiami, United StatesTaking people
- New YorkNew York, United StatesTaking people
- NorcrossNorcross, United StatesTaking people
- OceansideOceanside, United StatesTaking people
- Oklahoma CityOklahoma City, United StatesTaking people
- PikesvillePikesville, United StatesTaking people
- PortlandPortland, United StatesTaking people
- RedlandsRedlands, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- Sherman OaksSherman Oaks, United StatesTaking people
- SnellvilleSnellville, United StatesTaking people
- SpringfieldSpringfield, United StatesTaking people
- Staten IslandStaten Island, United StatesTaking people
- The BronxThe Bronx, United StatesTaking people
- Toms RiverToms River, United StatesTaking people
- TucsonTucson, United StatesTaking people
- Walnut CreekWalnut Creek, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Axsome Therapeutics, Inc.
- Trial code
- NCT07484217
- Record updated
- 13 October 2026
- Original description
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.Read full original descriptionShow less
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.
Inclusion: Currently meets the DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT; Excessive daytime sleepiness symptoms; Able to comply with study procedures; Male or female, aged 18 to 65 years inclusive.
Exclusion: Any clinically significant medical (e.g., OSA, narcolepsy), behavioral, or psychiatric disorder, other than MDD with EDS symptoms; Unable to comply with study procedures; Medically inappropriate for study participation in the opinion of the investigator.